Expression and Significance of LncRNA-MINCR and CDK2 mRNA in Primary Hepatocellular Carcinoma

Author(s): Jiangshan Lian, Xiaolin Zhang, Yingfeng Lu, Shaorui Hao, Zhe Zhang, Yida Yang*.

Journal Name: Combinatorial Chemistry & High Throughput Screening

Volume 22 , Issue 3 , 2019

Become EABM
Become Reviewer

Abstract:

Objective: To investigate the expression of long-chain non-coding RNA MINCR (LncRNAMINCR) and Cyclin-Dependent Kinase 2 (CDK2) mRNA in primary hepatocellular carcinoma, and to analyze the relationship between its expression and clinical pathological parameters and prognosis of hepatocellular carcinoma.

Methods: Seventy-five surgically resected primary hepatocellular carcinoma tissues and paracancerous tissues were selected. Real-time PCR was used to detect the expression of LncRNA-MINCR and CDK2 mRNA in hepatocellular carcinoma tissues and adjacent tissues. The relationship of clinicopathological parameters and prognosis between hepatocellular carcinoma and LncRNA-MINCR and CDK2 mRNA were analyzed. Pearson correlation coefficient describes the correlation between LncRNA-MINCR and CDK2 mRNA.

Results: The expression of LncRNA-MINCR and CDK2 mRNA in primary hepatocellular carcinoma tissues was higher than that in the adjacent tissues [(5.51±0.62) vs (1.62±0.51), (4.52±0.73) vs (1.85±0.95), P<0.05]. The expression of LncRNA-MINCR in the primary hepatocellular carcinoma group was positively correlated with CDK2 mRNA (r=0.352, P<0.05), and the expression of LncRNA-MINCR in the paracancerous tissue group was not correlated with CDK2 mRNA (r=0.024, P>0.05). LncRNA-MINCR expression was associated with TNM staging, lymph node metastasis, and cirrhosis (P<0.05). CDK2 mRNA expression was associated with tumor diameter, TNM stage, lymph node metastasis, and serum alpha-fetoprotein levels (P<0.05). The 3-year survival rate of patients with high expression of LncRNAMINCR was lower than that of LncRNA-MINCR low expression group [53.49% vs 77.38%, 2=13.024, P<0.05). The 3-year survival rate of patients with high CDK2 mRNA expression was lower than that of CDK2 mRNA low expression group [51.29] % vs 80.38%, 2 = 10.15, P < 0.05].

Conclusion: The expression of LncRNA-MINCR and CDK2 mRNA in primary hepatocellular carcinoma tissues increased significantly. The two play a synergistic role in the invasion, invasion and metastasis of hepatocarcinoma cells. High expression of LncRNA-MINCR and CDK2 mRNA indicates poor prognosis in patients with hepatocellular carcinoma.

Keywords: Malignant tumor, primary hepatocellular carcinoma, LncRNA-MINCR, CDK2 mRNA, clinicopathological parameters, prognosis, gene expression.

[1]
Ulitsky, I.; Bartel, D.P. LincRNAs: genomics,evolution,and mechanisms. Cell, 2013, 154(1), 26-46.
[2]
DiStefano, J.K. Long noncoding RNAs in the initiation, progression, and metastasis of hepatocellular carcinoma. Noncoding RNA Res., 2017, 2(3-4), 129-136.
[3]
Doose, G.; Haake, A.; Bernhart, S.H.; López, C.; Duggimpudi, S.; Wojciech, F.; Bergmann, A.K.; Borkhardt, A.; Burkhardt, B.; Claviez, A.; Dimitrova, L.; Haas, S.; Hoell, J.I.; Hummel, M.; Karsch, D.; Klapper, W.; Kleo, K.; Kretzmer, H.; Kreuz, M.; Küppers, R.; Lawerenz, C.; Lenze, D.; Loeffler, M.; Mantovani-Löffler, L.; Möller, P.; Ott, G.; Richter, J.; Rohde, M.; Rosenstiel, P.; Rosenwald, A.; Schilhabel, M.; Schneider, M.; Scholz, I.; Stilgenbauer, S.; Stunnenberg, H.G.; Szczepanowski, M.; Trümper, L.; Weniger, M.A. ICGC MMML-Seq Consortium.;Hoffmann, S.; Siebert, R.; Iaccarino, I.MINCR is a MYC-in-duced lncRNA able to modulate MYC’s transcriptional network in Burkitt lymphoma cells. Proc. Natl. Acad., 2015, 112(38), 5261-5270.
[4]
Malumbres, M.; Barbacid, M. Mammalian cyclin-dependent kinases. Trends Biochem. Sci., 2005, 2005(11), 630-641.
[5]
Gopinathan, L.; Tan, S.L.; Padmakumar, V.C.; Coppola, V.; Tessarollo, L.; Kaldis, P. Loss of CDK2 and cyclin A2 impairs cell proliferation and tumorigenesis. Cancer Res., 2014, 74(14), 3870-3879.
[6]
Torre, L.A.; Bray, F.; Siegel, R.L.; Ferlay, J.; Lortet-Tieulent, J.; Jemal, A. Global cancer statistics, 2012. CA Cancer J. Clin., 2015, 65, 87-108.
[7]
Chen, W.; Zheng, R.; Baade, P.D.; Zhang, S.; Zeng, H.; Bray, F.; Jemal, A.; Yu, X.Q.; He, J. Cancer statistics in China. 2015. CA Cancer J. Clin., 2016, 66, 115-132.
[8]
Niu, Z.; Liu, H.; Zhou, M.; Wang, H.; Liu, Y.; Li, X.; Xiong, W.; Ma, J.; Li, X.; Li, G. Knockdown of c-Myc inhibits cell proliferation by negatively regulating the CDK/Rb/E2F pathway in nasopharyngeal carcinoma cells. Acta Biochim. Biophys. Sin., 2015, 47(3), 183-191.
[9]
Forner, A.; Llovet, J.M.; Bruix, J. Hepatocellular carcinoma. Lancet, 2012, 379(9822), 1245-1255.
[10]
Shachaf, C.M.; Felsher, D.W. Tumor dormancy and MYC inactivation: pushing cancer to the brink of normalcy. Cancer Res., 2005, 65(11), 4471-4474.
[11]
Wang, S.H.; Yang, Y.; Wu, X.C.; Zhang, M.D.; Weng, M.Z.; Zhou, D.; Wang, J.D.; Quan, Z.W. Long non-coding RNA MINCR promotes gallbladder cancer progression through stimulating EZH2expression. Cancer Lett., 2016, 380(1), 122-133.
[12]
Sengupta, S.; Henry, R.W. Regulation of the retinoblastoma-E2F pathway by the ubiquitin-proteasome system. Biochim. Biophys. Acta, 2015, 1849(10), 1289-1297.
[13]
Wang, J.; Yang, T.; Xu, G.; Liu, H.; Ren, C.; Xie, W.; Wang, M. Cyclin-dependent kinase 2 promotes tumor proliferation and induces radio resistance in glioblastoma. Transl. Oncol., 2016, 9(6), 548-556.
[14]
Yang, C.C.; LaBaff, A.; Wei, Y.; Nie, L.; Xia, W.; Huo, L.; Yamaguchi, H.; Hsu, Y.H.; Hsu, J.L.; Liu, D.; Lang, J.; Du, Y.; Lien, H.C.; Li, L.Y.; Deng, R.; Chan, L.C.; Yao, J.; Kleer, C.G.; Hortobagyi, G.N.; Hung, M.C. Phosphorylation of EZH2 at T416 by CDK2 contributes to the malignancy of triple negative breast cancers. Am. J. Transl. Res., 2015, 7(6), 1009-1020.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 22
ISSUE: 3
Year: 2019
Page: [201 - 206]
Pages: 6
DOI: 10.2174/1386207322666190404151020
Price: $58

Article Metrics

PDF: 14
HTML: 2